Register for free to
view the full innovation profile.
The COVID-19 pandemic has emphasized the need for the global community to rapidly acquire a diverse arsenal of prevention and therapeutic options to address SARS-CoV-2. A flexible and robust solution is needed to impact the current threat and shorten the lead time for discovery of therapeutics for future outbreaks. To address this critical need and support our nation�s commitment to the health of the global community, Sandia National Laboratories has developed an antibody discovery platform for mitigating current and future biological threats.
About
Researchers at Sandia have identified and engineered highly potent SARS-CoV-2 antibodies with prophylactic and therapeutic efficacy against SARS-CoV-2 in a rodent model of severe infection and disease. These antibodies were identified using Sandia's proprietary humanized single-domain antibody library and are ideal for the treatment and prevention of mild to moderate COVID-19 disease. Development of second-generation antibodies with efficacy against emerging variants is underway with therapeutic properties comparable to currently deployed therapeutics. These antibody therapies can be used as the foundation for a commercial partner to move forward through their pipeline.
Key Benefits
Comparable to commercially available therapeutics Bypasses initial discovery and proceed to clinical evaluation Rapidly adaptable to current and future SARS-CoV-2 variants Versatile use- prophylactic/therapeutic/diagnostic Robustly expressed in high levels to meet clinical needs Single domain antibodies are stable/ highly soluble/ modular Structure enables them to target protein domains difficult to target by conventional antibodies Simplification of delivery as mRNA with single-chain construction
Applications
Bio and chemical defense Diagnostics Hospitals and clinics Pharmaceuticals, Medical research